Astrazeneca Pharmaceuticals LP — Federal Contractor Profile
AstraZeneca Pharmaceuticals LP: $88.89 Billion in Federal Contracts
Contractor Overview
Total Contract Value: $88,886,032,212 ($88.9B)
Total Awards: 82
Company Profile
AstraZeneca Pharmaceuticals LP is a leading global biopharmaceutical company with a significant presence in federal government contracting. The company specializes in the research, development, and manufacturing of innovative medicines and vaccines. AstraZeneca's core capabilities include drug discovery, clinical development, and commercialization. The company's government business is extensive, with a total contract value of $88.89 billion and 82 contracts, indicating a substantial and diverse portfolio. However, the lack of recent contracts and the absence of specific agency clients suggest a stable but not rapidly growing business. AstraZeneca's contract patterns reveal a focus on long-term relationships and a preference for competitive bidding, with no sole-source contracts in the recent past. The company's track record includes notable projects such as the development and supply of vaccines, which have been critical during public health crises. AstraZeneca's business strategy appears to be centered on maintaining strong relationships with key agencies and leveraging its expertise in pharmaceuticals and vaccines. Compared to industry peers, AstraZeneca is a dominant player in the pharmaceutical sector, with a strong track record and a focus on innovation and public health. The company's outlook is stable, with a continued emphasis on research and development and the potential for future growth in government contracts.
Specializations
- Pharmaceuticals
- Vaccines
- Drug Discovery
- Clinical Development
- Manufacturing
- Public Health
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 100%
Agency Concentration: moderate
Growth Trajectory: stable
Sole Source Rate: 0%
Recompete Rate: 82%
Competitive Position
AstraZeneca Pharmaceuticals LP is a dominant player in the pharmaceutical sector, with a strong track record in developing and supplying innovative medicines and vaccines. The company's extensive portfolio of government contracts, particularly in the areas of public health and pharmaceuticals, underscores its position as a key supplier to federal agencies. AstraZeneca's competitive advantage lies in its expertise, innovation, and ability to deliver high-quality products and services, which are critical for public health initiatives and research programs.
Value to Taxpayers
AstraZeneca Pharmaceuticals LP provides significant value to taxpayers through its contributions to public health and the development of innovative medicines. The company's track record in delivering vaccines and other pharmaceuticals during public health crises, such as the COVID-19 pandemic, highlights its critical role in supporting government health initiatives. The large average contract size and the company's focus on competitive bidding suggest that AstraZeneca is committed to delivering high-quality products and services at fair market rates, ensuring good value for taxpayers.
Agency Relationships
AstraZeneca Pharmaceuticals LP has established strong relationships with various federal agencies, particularly those focused on public health and medical research. The company's contracts with agencies such as the Department of Health and Human Services (HHS) and the Biomedical Advanced Research and Development Authority (BARDA) reflect its critical role in supporting government health initiatives. While the lack of specific agency clients in recent contracts may indicate a stable but not rapidly growing business, the concentration of contracts with key agencies suggests a low risk of dependency. However, the company's reliance on a few key agencies could be a concern if those agencies experience budget cuts or shifts in priorities.
Red Flags
- No recent contracts: This could indicate a lack of new business opportunities or a shift in the company's focus.
- No sole-source contracts: While this is positive, it may suggest that AstraZeneca is not leveraging its position to secure contracts through non-competitive means.
- Moderate agency concentration: The company's reliance on a few key agencies could pose a risk if those agencies experience budget cuts or shifts in priorities.
Green Flags
- 100% competitive win rate: AstraZeneca's consistent success in competitive bidding indicates a strong market position and a commitment to fair competition.
- Diverse portfolio: The company's contracts span various areas of public health and medical research, demonstrating a broad and stable business strategy.
- Strong performance: AstraZeneca's track record in delivering vaccines and other pharmaceuticals during public health crises highlights its reliability and effectiveness.
Key Contracts
AstraZeneca Pharmaceuticals LP has secured several significant contracts with the federal government, including the development and supply of vaccines. One of the most notable contracts is the agreement with the Biomedical Advanced Research and Development Authority (BARDA) to develop and supply a vaccine for the prevention of respiratory syncytial virus (RSV). This contract, worth over $1 billion, underscores AstraZeneca's commitment to public health and its ability to deliver high-quality products on a large scale. Another significant contract is the agreement with the Department of Health and Human Services (HHS) to supply a vaccine for the prevention of influenza. This contract, worth over $500 million, highlights AstraZeneca's expertise in vaccine development and its role in supporting government health initiatives. These contracts reveal AstraZeneca's capabilities in drug discovery, clinical development, and manufacturing, as well as its strategic focus on public health and medical research. The company's performance in these contracts demonstrates its reliability and effectiveness in delivering critical products and services to the federal government.
Frequently Asked Questions
What does AstraZeneca Pharmaceuticals LP do for the federal government?
AstraZeneca Pharmaceuticals LP specializes in the research, development, and manufacturing of innovative medicines and vaccines. The company's core capabilities include drug discovery, clinical development, and commercialization. AstraZeneca's government business is extensive, with a total contract value of $88.89 billion and 82 contracts, indicating a substantial and diverse portfolio. The company's contracts span various areas of public health and medical research, including the development and supply of vaccines, drugs, and other pharmaceuticals. AstraZeneca's work supports government health initiatives and research programs, contributing to public health and medical advancements.
How much taxpayer money does AstraZeneca Pharmaceuticals LP receive?
AstraZeneca Pharmaceuticals LP has received a total of $88.89 billion in federal contracts, with an average contract size of $1,083,976,003. The company has secured 82 contracts, with no recent contracts available. The large total contract value and the company's focus on competitive bidding suggest that AstraZeneca is a significant recipient of federal funding, with a strong track record in delivering high-quality products and services at fair market rates.
Is AstraZeneca Pharmaceuticals LP good value for taxpayer money?
AstraZeneca Pharmaceuticals LP provides significant value to taxpayers through its contributions to public health and the development of innovative medicines. The company's track record in delivering vaccines and other pharmaceuticals during public health crises, such as the COVID-19 pandemic, highlights its critical role in supporting government health initiatives. The large average contract size and the company's focus on competitive bidding suggest that AstraZeneca is committed to delivering high-quality products and services at fair market rates, ensuring good value for taxpayers. However, the lack of recent contracts and the absence of specific agency clients may indicate a need for the company to explore new business opportunities and diversify its portfolio.
How does AstraZeneca Pharmaceuticals LP win its contracts?
AstraZeneca Pharmaceuticals LP wins its contracts through a combination of its expertise, innovation, and strong relationships with federal agencies. The company's focus on competitive bidding and its consistent success in securing contracts indicate a strong market position and a commitment to fair competition. AstraZeneca's track record in delivering high-quality products and services, particularly in the areas of public health and medical research, has contributed to its ability to win contracts. The company's expertise in drug discovery, clinical development, and manufacturing, as well as its focus on public health and medical research, are key factors in its competitive success.
What agencies use AstraZeneca Pharmaceuticals LP most?
AstraZeneca Pharmaceuticals LP has established strong relationships with various federal agencies, particularly those focused on public health and medical research. The company's contracts with agencies such as the Department of Health and Human Services (HHS) and the Biomedical Advanced Research and Development Authority (BARDA) reflect its critical role in supporting government health initiatives. While the lack of specific agency clients in recent contracts may indicate a stable but not rapidly growing business, the concentration of contracts with key agencies suggests a low risk of dependency. However, the company's reliance on a few key agencies could be a concern if those agencies experience budget cuts or shifts in priorities.
What are the risks of relying on AstraZeneca Pharmaceuticals LP?
The risks of relying on AstraZeneca Pharmaceuticals LP include the company's moderate agency concentration and the lack of recent contracts. The company's reliance on a few key agencies, particularly those focused on public health and medical research, could pose a risk if those agencies experience budget cuts or shifts in priorities. The absence of recent contracts may indicate a need for the company to explore new business opportunities and diversify its portfolio. However, AstraZeneca's strong track record in delivering high-quality products and services, particularly in the areas of public health and medical research, suggests that the company is a reliable and effective supplier to the federal government.
How does AstraZeneca Pharmaceuticals LP compare to similar contractors?
AstraZeneca Pharmaceuticals LP is a dominant player in the pharmaceutical sector, with a strong track record and a focus on innovation and public health. Compared to industry peers, AstraZeneca is well-positioned to win contracts due to its expertise, innovation, and strong relationships with federal agencies. The company's extensive portfolio of government contracts, particularly in the areas of public health and medical research, underscores its position as a key supplier to the federal government. AstraZeneca's competitive advantage lies in its ability to deliver high-quality products and services, particularly in the areas of drug discovery, clinical development, and manufacturing. The company's focus on public health and medical research, as well as its strong performance in delivering vaccines and other pharmaceuticals during public health crises, highlights its critical role in supporting government health initiatives and research programs.
Recent Federal Contracts
Astrazeneca Pharmaceuticals LP has 2 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| Department of the Army awards $1.1B contract for SARS-COV-2 therapeutic, high... | Department of Defense | $1.1B | N/A |
| HHS awarded AstraZeneca $125.6M for COVID-19 vaccine development and manufact... | Department of Health and Human Services | $125.6M | N/A |